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Randomized Controlled Trials have had many sta-
tistical developments since their introduction into
modern medicine sixty years ago. While many of the
advances have addressed general design and analy-
sis issues, most have been motivated by or focused
on assessment of efficacy in contrast to safety. The
reporting of harms is demonstrably weak (Ioanni-
dis and Lau, 2001; Loke and Derry, 2001) and, in
spite of the CONSORT guideline on harms (Ioan-
nidis et al., 2004), continues to show some deficien-
cies (Pitrou et al., 2009). Analytical developments
focused on harms have been very limited, reflecting
lack of statistical effort employed in that area as well
as perhaps a general neglect of the less exciting area
of safety.
DuMouchel made a major contribution to extract-
ing useful information from spontaneous reports us-
ing Bayesian methods (DuMouchel, 1999; DuMou-
chel and Pregibon, 2001). This paper (DuMouchel,
2012) is potentially an important advance in assess-
ing data on harms from randomized trials. As an
incidental point, it is possible it will also have ap-
plication in observational studies as well.
There are several really important features of
MBLR as set out by DuMouchel:
(1) It addresses a clinically relevant problem, not
addressed by standard methods. The problem being
that it is difficult if not impossible to prespecify pos-
sible harms in terms of formal hypotheses and the
multiple medically related issues need to be seen as
a broad picture as well as being reflected by nar-
row medical terms. In practice, also the data may
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be very limited because serious harms are rare for
medicines reaching the market.
(2) It addresses at least part of the problem of
multiplicity of many possible hypotheses of harm.
(3) It avoids the epidemiological dilemma of lump-
ing or splitting terms which can lead to reduced sen-
sitivity or simple loss of statistical power. It also
avoids the difficulty caused by composite outcomes
which, although they have their place in assessing
efficacy, have problems in that context but poten-
tially worse problems in the context of safety.
(4) It provides medically useful and interpretable
estimates of effects while retaining a good statisti-
cal foundation. The modeling is consistent for each
response variable related to a possible harm, and
can be used in trials which are primarily aimed at
testing for efficacy.
(5) It does not seem heavily reliant on the par-
ticular form of the Bayesian Priors being used.
The potential of the method is therefore very con-
siderable and seems destined to be used by the phar-
maceutical industry and may eventually be encour-
aged by regulators if it is shown in practice to be use-
ful, applicable and reasonably easily implemented.
Nothing in life is perfect though! It does require
prespecification of a group of medically-related terms,
expressed as simple binary responses and expected
to behave in a similar manner (on a relative or odds
ratio scale)—showing exchangeability in Bayesian
parlance. This may not always be simple to do in
practice, and even with the use of a hierarchical
medical dictionary like MedDRA which has over
16,000 “preferred terms,” the choice of the number
of terms and how wide a range is included will not al-
ways be easy. There is then a danger that a nonpre-
specified analysis may reach the conclusion desired
by the analyst or sponsor. It will be interesting to see
if the MBLR method can be applied to the more lim-
ited number of terms in the internationally agreed
“Standardized MedDRA Queries” which are already
groupings of terms from one or more MedDRA Sys-
tem Organ Classes (SOCs) that relate to a defined
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medical condition or area of interest. Similarly, it
may be possible to use a form of cluster analysis to
provide medically sensible groupings based on one
set of data (not necessarily from RCTs) and then to
apply MBLR using these empirically derived group-
ings.
The covariates in this formulation also have to be
expressed as binary explanatory variables, though
this is not a major problem.
The important idea of “borrowing strength” seems
here to be less dependent on the form of the prior
than is the method suggested by Berry and Berry
(2004); see Prieto-Merino and Evans (2009).
One issue that may be of relevance is how well
this borrowing of strength works in slightly different
contexts. In this example, all ten terms are showing
conventionally “statistically significant” differences
with treatment so it could be argued that the MBLR
adds little to the understanding. Display 4 shows
this and though there is what may be a helpful ef-
fect for estimation of the OR for anuria, there is
(as expected given the data) relatively little effect
elsewhere. The consistent effect in this data set may
be rather rare in other situations where the MBLR
might be used and more investigation of its proper-
ties is required. The simulation provides some help
and reassurance that the method will perform well
under some conditions, but real life may be more
complex.
The effects of sample size, number of covariates
and number of response variables studied on the
overall results is not yet clear.
It is stated that the computational burden is not
great and the algorithms suggested do not require
Gibbs sampling or Markov Chain Monte Carlo meth-
ods, so making the method more accessible to med-
ical researchers. This reader is not sure how easy
it will be to implement MBLR in more standard
software and whether investigators will find it eas-
ier than using WINBUGS or similar public domain
software is not clear.
In spite of these possible problems, the MBLR
method shows very great potential and is a real ad-
vance that will require further testing. It may be
a way of doing meta-analysis of RCT data where
multiple response variables are studied both for ef-
ficacy and for safety. Might it avoid the composite
variable problems in analyses of RCTs for efficacy?
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